T. Satoh

A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S‐1 plus intravenous paclitaxel for serosa‐positive gastric cancer

T. Yasuda, Y. Chiba, H. Furukawa, 2015, Journal of surgical oncology.

LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer

R. García-Carbonero, T. Yoshino, S. Lonardi, 2022, Annals of Oncology.

80P Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN

E. Oki, E. Sokol, D. Fabrizio, 2021, Annals of Oncology.

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

R. Finn, L. Wyrwicz, E. Assenat, 2022, Annals of Oncology.

A phase 2 study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403).

D. Sakai, Y. Kurokawa, T. Shimokawa, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.

K. Muro, T. Tamura, W. Kang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.